Drug Profile
Monolaurin - Dare Bioscience
Alternative Names: AU1; DARE-GML; Glycerol monolaurate - Hennepin Life Sciences; GML GelLatest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Hennepin Life Sciences
- Developer Dare Bioscience; Hennepin Life Sciences
- Class Anti-inflammatories; Antipruritics; Esters; Glycerides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Gynaecological infections
- No development reported Urinary tract infections
Most Recent Events
- 05 Apr 2024 Dare Bioscience has patent protection for monolaurin in USA and in rest of the World
- 05 Apr 2024 Dare Bioscience has patents pending for monolaurin in USA and in rest of the World
- 06 Feb 2023 Pharmacodynamics data from preclinical trial in Gynaecological-infections released by Dare Bioscience